Anemia and survival in childhood acute lymphoblastic leukemia

Haematologica

Volumn 93, Issue 11, 2008, Pages 1652-1657

  Teuffel, Oliver ^a   Stanulla, Martin ^b   Cario, Gunnar ^c   Ludwig, Wolf D ^d   Rottgers, Silja ^e   Schafer, Beat W ^a   Zimmermann, Martin ^b   Schrappe, Martin ^c   Niggli, Felix K ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HELIOS KLINIKUM BERLIN BUCH   (Germany)

^e UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Anemia; Childhood acute lymphoblastic leukemia; Myeloid suppression; TEL AML1

Indexed keywords

HEMOGLOBIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ARTICLE; B CELL LEUKEMIA; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; DISEASE SEVERITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; T CELL LEUKEMIA;

ANEMIA; BURKITT LYMPHOMA; CHILD; COHORT STUDIES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; FUSION PROTEINS, BCR-ABL; HEMOGLOBINS; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, T-CELL; LEUKOCYTE COUNT; MUTATION; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 55549091052     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13156     Document Type: Article

References (42)

1. Santana VM, Dodge RK, Crist WM, Rivera GK, Look AT, Behm FG, et al. Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia. Leukemia 1990;4:87-90.
2. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALLBFM 86. Blood 1994;84:3122-33.
3. Donadieu J, Auclerc MF, Baruchel A, Leblanc T, Landman-Parker J, Perel Y, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group. Br J Haematol 1998;102:729-39.
4. Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. UK Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 2001;113:103-14.
5. Dowd MD, Morgan ER, Langman CB, Murphy S. Serum erythropoietin levels in children with leukemia. Med Pediatr Oncol 1997;28:259-67.
6. Corazza F, Beguin Y, Bergmann P, André M, Ferster A, Devalck C, et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood 1998;92:1793-8.
7. Greaves MF, Janossy G, Peto J, Kay H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol 1981;48:179-97.
8. Pullen DJ, Boyett JM, Crist WM, Falletta JM, Roper M, Dowell B, et al. Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. Ann N Y Acad Sci 1984;428:26-48.
9. Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993;82:343-62.
10. Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990;75:166-73.
11. Steinherz PG, Siegel SE, Bleyer WA, Kersey J, Chard R Jr, Coccia P, et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure. Cancer 1991;68:751-8.
12. Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990;75:174-9.
13. Advani S, Pai S, Venzon D, Adde M, Kurkure PK, Nair CN, et al. Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimen. Ann Oncol 1999;10:167-76.
14. Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999;13:1696-707.
15. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-48.
16. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALLBFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-22.
17. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33.
18. Harms DO, Janka-Schaub GE. Cooperative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000;14:2234-9.
19. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8.
20. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-75.
21. Pui CH, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003;290:2001-7.
22. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. German-Austrian-Swiss ALL-BFM Study Group. Blood 2008;111:4477-89.
23. Kaplan EI, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
25. Kalbfleisch EL, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley 1980. p. 163-88.
26. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
27. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-9.
28. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996;88:4252-8.
29. Liang DC, Chou TB, Chen JS, Shurtleff SA, Rubnitz JE, Downing JR, et al. High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996;10:991-3.
30. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997;90:571-7.
31. Rubnitz JE, Downing JR, Pui CH, Shurtleff SA, Raimondi SC, Evans WE, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997;15:1150-7.
32. Takahashi Y, Horibe K, Kiyoi H, Miyashita Y, Fukuda M, Mori H, et al. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998;20:190-5.
33. Maloney K, McGavran L, Murphy J, Odom L, Stork L, Wei Q, et al. TELAML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia 1999;13:1708-12.
34. Jamil A, Theil KS, Kahwash S, Ruymann FB, Klopfenstein KJ. TEL/AML-1 fusion gene. Its frequency and prognostic significance in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2000;122:73-8.
35. Tsang KS, Li CK, Chik KW, Shing MM, Tsoi WC, Ng MH, et al. TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong. Am J Hematol 2001;68:91-8.
36. Ozbek U, Sirma S, Agaoglu L, Yuksel L, Anak S, Yildiz I, et al. Prognostic significance of the TELAML1 fusion gene in pediatric acute lymphoblastic leukemia in Turkey. J Pediatr Hematol Oncol 2003; 25:204-8.
37. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, et al. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Clin Cancer Res 2005;11:2974-80.
38. Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006;107:4508-13.
39. Lin D, Liu SH, Zhu XF, Bo LJ, Li CW, Chen YM, et al. [Study of the childhood acute lymphoblastic leukemia with t(12;21)]. Zhonghua Xue Ye Xue Za Zhi 2004;25:17-21.
40. Guo X, Li Q, Zhu YP, Zhou CY, Gao J, Li XH, et al. [Comparative study on clinical features between TELAML1 positive and negative childhood acute lymphoblastic leukemia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007;24:560-3.
41. Hirt A, Leibundgut K, Luthy AR, von der Weid N, Wagner HP. Cell birth and death in childhood acute lymphoblastic leukaemia: how fast does the neoplastic cell clone expand? Br J Haematol 1997;98:999-1001.
42. Kanerva J, Saarinen-Pihkala UM, Niini T, Riikonen P, Möttönen M, Mäkipernaa A, et al. Favorable outcome in 20-year follow-up of children with very-low-risk ALL and minimal standard therapy, with special reference to TEL-AML1 fusion. Pediatr Blood Cancer 2004;42:30-5.